ストックスクリーナーアプリを入手
1.31
1.50%
-0.02
アフターアワーズ：
1.31
前日終値:
$1.33
開ける：
$1.32
24時間の取引高:
438.13K
Relative Volume:
0.67
時価総額：
$146.30M
収益：
-
当期純損益:
$-24.22M
株価収益率:
-4.6802
EPS:
-0.2799
ネットキャッシュフロー:
$-17.13M
1週間 パフォーマンス:
-4.38%
1か月 パフォーマンス:
-7.09%
6か月 パフォーマンス:
+20.18%
1年 パフォーマンス:
+13.91%
1日の値動き範囲:
$1.28
$1.36
1週間の範囲:
$1.28
$1.395
52週間の値動き範囲:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.31 | 148.53M | 0 | -24.22M | -17.13M | -0.2799 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
User - The Chronicle-Journal
MSN Money - MSN
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - ChartMill
Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com
Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com
Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart
Positive Results on MAVERIC Phase III Trial and Published ARCHER - openPR.com
CRDL (Cardiol Therapeutics Inc.) Q4 2025 narrower than expected loss lifts shares more than 7 percent higher today.Revenue Diversification - Xã Thanh Hà
Is Cardiol (CRDL) stock sensitive to volatility (Drops Sharply) 2026-04-22Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Metro Q2 2026 Earnings Rise On Margins, Buybacks And Pharmacy Growth - thedeepdive.ca
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year HighHere's Why - MarketBeat
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Fixing Heart Disease Tied to Sudden Death in Young People | David ElsleyCardiol Therapeutics - thedeepdive.ca
Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9%Here's What Happened - MarketBeat
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - MarketBeat
Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Australia
Cardiol Therapeutics CEO to discuss drug trials in interview - Investing.com
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart
$30 Billion Per Year US Heart Failure Market Presents Huge - openPR.com
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
3 Biotech Stocks Surge with Momentum - National Today
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan
Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Cardiol Therapeutics Secures Funding Through 2027 Amid Clinical Advancements - AD HOC NEWS
CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Research Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cardiol Therapeutics: A 2026 Inflection Point on the Horizon - AD HOC NEWS
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):